Condition: Basal Cell Carcinoma (BCC) · First Line Treatment · Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
The study is an open-label, singel arm, prospective, multicenter phase II trial evaluating the efficacy and safety of Cemiplimab when applied as first-line therapy in patients with locally advanced basal cell carcinoma (BCC), which were not pretreated with hedgehog inhibitors (HHI).
This description comes directly from the study's public registry record.
Ralf Gutzmer, Prof. Dr. med. · +49 571/ 790 4501 · Ralf.Gutzmer@Muehlenkreiskliniken.de
Michelle Tez · +4969 / 5899 787 65 · tez.michelle@ikf-khnw.de
Always discuss trial participation with your own doctor first.
| Helios Klinikum Erfurt | Erfurt, Germany | Recruiting |
| Universitätsklinikum Erlangen | Erlangen, Germany | Recruiting |
| Nationales Centrum für Tumorerkrankungen (NCT) | Heidelberg, Germany | Recruiting |
| Universitätsklinikum Leipzig | Leipzig, Germany | Recruiting |
| Johannes Wesling Klinikum | Minden, Germany | Recruiting |
| Helios Klinikum Oberhausen | Oberhausen, Germany | Recruiting |
| Universitätsklinikum Tübingen | Tübingen, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06981325